Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with (223)Radium-dichloride: a national multicenter study

OBJECTIVE: Radium-223 ((223)Ra) has been approved for treatment in patients with metastatic castration-resistant prostatic cancer (mCRPC) and bone metastasis. This α-emitting radionuclide has a beneficial effect on pain and is also capable to increase overall survival (OS). Several studies evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Frantellizzi, Viviana, Monari, Fabio, Mascia, Manlio, Costa, Renato, Rubini, Giuseppe, Spanu, Angela, Di Rocco, Arianna, Lodi Rizzini, Elisa, Cindolo, Luca, Licari, Maria, Lavelli, Valentina, Nuvoli, Susanna, De Angelis, Cristina, Dionisi, Valeria, Ferrari, Cristina, De Vincentis, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515961/
https://www.ncbi.nlm.nih.gov/pubmed/32654030
http://dx.doi.org/10.1007/s12149-020-01501-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515961/
https://www.ncbi.nlm.nih.gov/pubmed/32654030
http://dx.doi.org/10.1007/s12149-020-01501-7

Ejemplares similares